Please ensure Javascript is enabled for purposes of website accessibility

Why Translate Bio Shares Are Tanking Today

By Keith Speights - Mar 18, 2021 at 11:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are disappointed with the company's latest clinical update.

What happened

Shares of Translate Bio (TBIO) were tanking 31.8% as of 11:26 a.m. EDT on Thursday. The big drop came after the company announced results following the market close on Wednesday from a second interim data analysis of a phase 1/2 study of MRT5005 in treating cystic fibrosis (CF).

So what

The big story from Translate Bio's latest results was that no clear improvement was observed in lung function among patients receiving MRT5005. SVB Leerink analyst Geoffrey Porges summed it up in a note to investors by stating, "the trial failed."

However, the primary focus of the phase 1/2 study was to evaluate the safety and tolerability of MRT5005. Translate Bio said that repeat dosing of the experimental drug was "generally safe and well tolerated with no serious adverse events."

Clipboard with a document titled "Cystic Fibrosis" next to a stethoscope, pills, and a syringe

Image source: Getty Images.

Ann Barbier, Translate Bio's chief medical officer, said in a statement, "Based on the first and second interim analyses, we believe we have achieved a safety profile that supports repeat dosing of inhaled mRNA and further advancement of the pulmonary platform for chronic dosing."

Still, investors clearly hoped to see at least some indication of efficacy for MRT5005. That's why Translate Bio's results were so disappointing.

Now what

Translate Bio plans to continue studying MRT5005 in treating CF. However, the main potential catalysts for the biotech stock could come from its other pipeline programs. Translate Bio and its partner Sanofi recently began a phase 1/2 study of their messenger RNA COVID-19 vaccine candidate. The companies also expect to advance an experimental flu vaccine into clinical testing later this year. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Translate Bio, Inc. Stock Quote
Translate Bio, Inc.
TBIO
Sanofi Stock Quote
Sanofi
SNY
$53.15 (0.47%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.